Skip to main content
Smart Investors Daily
FD

NASDAQ · FDMT

4D Molecular Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$12.23

Down-$0.94 (-7.69%)

Updated Nov 17, 2026, 1:44 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
510.45M
P/E ratio
-2.93
Dividend yield
0.00%
52-week range
$6.96 – $16.93
Volume
813.8K
Avg. volume
843.04K

Price performance · FDMT

FDMT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

FDMT closed at $12.23 after 20 trading sessions, down 0.49% for the selected period.

Last close
$12.23
Period change
-0.49%
Period low
$10.80
Period high
$13.10
Daily close
View OHLC price history
FDMT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$11.62$12.3698$10.975$12.23813.8K
Nov 12, 2026$12.59$12.86$12.04$12.115897.22K
Nov 11, 2026$12.48$13.03$12.38$12.99837.18K
Nov 10, 2026$12.47$12.765$12.15$12.461.08M
Nov 9, 2026$12.42$12.71$12.15$12.48879.81K
Nov 6, 2026$11.46$12.57$11.28$12.25993.26K
Nov 5, 2026$12.105$12.105$11.16$11.251.6M
Nov 4, 2026$12.36$12.44$11.51$12.28764.67K
Nov 3, 2026$11.52$12.085$11.455$11.95740.41K
Nov 2, 2026$11.88$12.06$11.16$11.37734.78K
Oct 30, 2026$12.49$12.88$11.735$11.90683.49K
Oct 29, 2026$13.00$13.456$12.57$12.78848.93K
Oct 28, 2026$11.89$12.96$11.73$12.931.19M
Oct 27, 2026$10.96$11.99$10.75$11.961.13M
Oct 26, 2026$10.74$11.29$10.62$11.031.08M
Oct 23, 2026$11.74$11.75$10.675$10.80996.14K
Oct 22, 2026$12.60$13.12$11.68$11.851.35M
Oct 21, 2026$13.12$13.45$12.605$12.622.02M
Oct 20, 2026$12.29$13.39$12.29$13.10725.37K
Oct 19, 2026$12.36$12.68$12.21$12.29855.68K

Latest FDMT news

The latest Smart Investors Daily articles mentioning FDMT.

FDMT research

Overview

Company profile and research snapshot.

Company profile

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$25.33
Implied upside
—
Analysts
—
FDMT recent ratings
DateFirmRatingTarget
Oct 22, 2026HC Wainwright & Co.Buy—
Oct 6, 2026Chardan CapitalBuy—
Sep 29, 2026B of A SecuritiesBuy—
Sep 14, 2026Cantor FitzgeraldOverweight—
Jul 31, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates

Zoetis (ZTS) delivered earnings and revenue surprises of +15.89% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo · Nov 3, 2026

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in November and December: Guggenheim 3rd Annual Healthcare Innovation Confe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.